Barclays’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-3,976
| Closed | -$73K | – | 5385 |
|
|
2020
Q4 | $73K | Sell |
3,976
-1,716
| -30% | -$31.3K | ﹤0.01% | 4258 |
|
|
2020
Q3 | $104K | Buy |
+5,692
| New | +$95.7K | ﹤0.01% | 4233 |
|
|
2020
Q1 | – | Sell |
-6
| Closed | – | – | 6660 |
|
|
2019
Q4 | $0 | Sell |
6
-5,961
| -100% | -$99.4K | ﹤0.01% | 7076 |
|
|
2019
Q3 | $89K | Sell |
5,967
-1,832
| -23% | -$24.7K | ﹤0.01% | 5568 |
|
|
2019
Q2 | $129K | Buy |
7,799
+4,445
| +133% | +$72.6K | ﹤0.01% | 5493 |
|
|
2019
Q1 | $58K | Buy |
+3,354
| New | +$60.9K | ﹤0.01% | 5761 |
|
|
2018
Q4 | – | Sell |
-4,348
| Closed | -$79K | – | 7575 |
|
|
2018
Q3 | $79K | Buy |
4,348
+3,497
| +411% | +$71.7K | ﹤0.01% | 5764 |
|
|
2018
Q2 | $16K | Sell |
851
-749
| -47% | -$14K | ﹤0.01% | 6322 |
|
|
2018
Q1 | $28K | Sell |
1,600
-600
| -27% | -$11K | ﹤0.01% | 6289 |
|
|
2017
Q4 | $25K | Buy |
+2,200
| New | +$23K | ﹤0.01% | 6191 |
|
|
2017
Q3 | – | Sell |
-9,651
| Closed | -$84K | – | 7150 |
|
|
2017
Q2 | $84K | Buy |
9,651
+9,595
| +17,134% | +$84.5K | ﹤0.01% | 5045 |
|
|
2017
Q1 | $0 | Sell |
56
-89
| -61% | -$1.08K | ﹤0.01% | 7095 |
|
|
2016
Q4 | $2K | Sell |
145
-6
| -4% | -$80 | ﹤0.01% | 6408 |
|
|
2016
Q3 | $2K | Buy |
+151
| New | +$2.14K | ﹤0.01% | 6305 |
|
|
2015
Q4 | – | Sell |
-51
| Closed | -$1K | – | 6822 |
|
|
2015
Q3 | $1K | Sell |
51
-137
| -73% | -$3.41K | ﹤0.01% | 6666 |
|
|
2015
Q2 | $7K | Buy |
+188
| New | +$6.07K | ﹤0.01% | 6301 |
|
Barclays's CBMG Position: Q1 2021 in Review
Barclays sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 3,976 shares — an estimated $73K sold.
Barclays first reported a position in CBMG in Q2 2015 and held it in 16 quarters. The position peaked at $129K in Q2 2019. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Barclays reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Barclays sold 3,976 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $73K.
- Barclays first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 16 quarters.
- Barclays's Cellular Biomedicine Group, Inc. position peaked at $129K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.